Tenax Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.48 Insider Own9.10% Shs Outstand26.33M Perf Week-6.73%
Market Cap4.62M Forward P/E- EPS next Y-1.79 Insider Trans0.00% Shs Float8.71M Perf Month-24.24%
Income-12.20M PEG- EPS next Q-2.28 Inst Own16.30% Short Float / Ratio24.77% / 0.52 Perf Quarter-77.88%
Sales- P/S- EPS this Y-20.70% Inst Trans29.96% Short Interest2.16M Perf Half Y-85.72%
Book/sh0.15 P/B3.27 EPS next Y106.10% ROA-214.10% Target Price43.00 Perf Year-96.93%
Cash/sh- P/C- EPS next 5Y- ROE-294.60% 52W Range0.45 - 17.00 Perf YTD-77.98%
Dividend- P/FCF- EPS past 5Y44.80% ROI- 52W High-97.11% Beta2.23
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low8.54% ATR0.11
Employees8 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)34.11 Volatility8.84% 17.84%
OptionableNo Debt/Eq0.00 EPS Q/Q26.50% Profit Margin- Rel Volume0.30 Prev Close0.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.19M Price0.49
Recom2.00 SMA20-13.87% SMA50-56.73% SMA200-86.07% Volume1,323,012 Change1.57%
May-18-17Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14Initiated MLV & Co Buy $7
Nov-18-14Initiated WallachBeth Buy $12
Mar-22-23 08:45AM
Feb-17-23 07:05AM
Feb-15-23 08:05AM
Feb-07-23 12:10PM
Feb-03-23 08:19AM
10:43AM Loading…
Feb-02-23 10:43AM
Feb-01-23 04:31PM
Jan-04-23 08:00AM
Nov-03-22 07:16AM
Oct-10-22 08:30AM
Sep-15-22 09:29AM
Aug-28-22 09:23AM
Aug-23-22 05:58AM
Jul-01-22 07:52AM
08:30AM Loading…
May-25-22 08:30AM
May-23-22 08:30AM
May-19-22 08:18AM
May-18-22 08:30AM
Apr-01-22 09:25AM
Mar-31-22 08:30AM
Mar-30-22 05:00PM
Jan-31-22 04:10PM
Jan-12-22 08:30AM
Jan-05-22 11:48AM
Jan-04-22 08:30AM
Nov-18-21 11:54AM
Nov-16-21 08:30AM
Oct-06-21 08:30AM
Sep-28-21 08:30AM
10:43AM Loading…
Sep-20-21 10:43AM
Sep-09-21 08:00AM
Aug-17-21 08:00AM
Aug-12-21 08:00AM
Aug-05-21 08:00AM
Jul-16-21 12:40PM
Jul-07-21 08:00AM
Jun-14-21 04:25PM
Jun-10-21 08:30AM
Jun-07-21 04:52PM
May-17-21 05:15PM
Apr-14-21 07:45AM
Apr-09-21 11:38AM
Apr-07-21 04:45PM
Mar-31-21 04:45PM
Mar-04-21 08:30AM
Mar-02-21 08:15AM
Jan-20-21 10:30AM
Jan-19-21 07:45AM
Dec-29-20 04:29PM
Dec-03-20 07:47AM
Nov-29-20 07:28PM
Nov-16-20 04:45PM
Nov-10-20 08:30AM
Nov-06-20 08:30AM
Oct-15-20 08:30AM
Oct-02-20 08:30AM
Sep-01-20 10:44AM
Aug-31-20 08:30AM
Aug-28-20 10:54AM
Aug-17-20 08:00AM
Jul-20-20 08:45AM
Jul-06-20 07:50PM
Jun-03-20 09:41AM
Jun-02-20 07:30AM
Jun-01-20 05:30AM
May-29-20 01:07PM
Apr-13-20 05:55AM
Apr-09-20 08:30AM
Mar-19-20 10:16AM
Mar-12-20 08:30AM
Feb-21-20 08:30AM
Jan-21-20 06:15AM
Jan-13-20 08:30AM
Dec-20-19 12:03PM
Nov-04-19 10:45AM
Oct-31-19 08:00AM
Sep-20-19 03:11PM
Sep-12-19 09:15AM
Aug-29-19 08:00AM
Aug-23-19 08:00AM
Jul-16-19 12:23PM
Jun-12-19 11:25AM
Apr-11-19 10:15AM
Mar-11-19 03:20PM
Feb-21-19 01:35PM
Feb-04-19 08:30AM
Jan-04-19 08:30AM
Dec-11-18 04:00PM
Dec-07-18 01:02PM
Nov-26-18 11:00AM
Nov-21-18 03:21PM
Nov-19-18 08:00AM
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.